Edition:
United States

EnteroMedics Inc (ETRM.OQ)

ETRM.OQ on NASDAQ Stock Exchange Capital Market

0.14USD
4:00pm EDT
Change (% chg)

$-0.01 (-6.25%)
Prev Close
$0.14
Open
$0.14
Day's High
$0.15
Day's Low
$0.13
Volume
2,562,014
Avg. Vol
1,368,236
52-wk High
$4.94
52-wk Low
$0.11

ETRM.OQ

Chart for ETRM.OQ

About

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $10.00
Shares Outstanding(Mil.): 69.70
Dividend: --
Yield (%): --

Financials

  ETRM.OQ Industry Sector
P/E (TTM): -- 45.60 36.83
EPS (TTM): -2.98 -- --
ROI: -762.74 7.63 13.93
ROE: -- 9.71 14.84

BRIEF-EnteroMedics appoints Dan Gladney as chairman of the board of directors

* Announces appointment of Dan Gladney as chairman of the board of directors

Sep 27 2016

BRIEF-EnteroMedics names Scott Youngstrom as CFO

* EnteroMedics announces appointment of Scott Youngstrom as chief financial officer and chief compliance officer

Sep 07 2016

BRIEF-CVI Investments Inc reports 9.9 pct passive stake in Enteromedics Inc

* CVI Investments Inc reports 9.9 pct passive stake in enteromedics inc, as of August 18, 2016 - Sec Filing Source - http://bit.ly/2cetnP4 Further company coverage:

Aug 26 2016

BRIEF-Enteromedics names Gary Blackford to board of directors

* Enteromedics announces appointment of Gary Blackford to its board of directors Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Aug 17 2016

BRIEF-EnteroMedics publishes 24 month recharge clinical study data in obesity surgery

* VBloc therapy demonstrates durable weight loss, reduction of comorbidities, and favorable safety profile at 24 months

Aug 15 2016

BRIEF-Enteromedics Q2 loss per share $0.49

* Q2 sales $276,000 Source text for Eikon: Further company coverage:

Aug 04 2016

BRIEF-Enteromedics reports Q1 loss per share $0.94

* Q1 loss per share $0.94 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 05 2016

BRIEF-Enteromedics closes $6.25 mln third tranche of previously-announced offering

* Enteromedics announces closing of $6.25 million third tranche of previously-announced convertible notes offering Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 03 2016

BRIEF-Enteromedics announces publication of results showing significantly greater weight loss in vBloc patients

* Enteromedics announces publication of results showing significantly greater weight loss in vBloc patients with moderate obesity

Apr 05 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.